Guideline adherence to oncologic therapy recommendations in gastrointestinal tumor boards and deviations in their implementation.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026807

Enrollment

800

Registered

2021-10-28

Start date

2021-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer, AEG/ Gastric cancer, GIST, Pancreatic cancer, Biliary tumors, Neuroendocrine tumors, Small intestine cancer, Pseudomyxoma peritonei (LAMN), Colorectal Cancer, Anal cancer

Interventions

Group 1: Retrospective determination of guideline and tumor board adherence to all therapy recommendations from the gastrointestinal tumor boards of Leipzig University Hospital from January 2020 - Dec

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Tumor boards with new therapy recommendations for patients with malignant gastrointestinal tumors

Exclusion criteria

Exclusion criteria: Tumor boards without therapy recommendation, tumor boards for patients with benign tumors or tumor precursors, tumor boards of minors (<18 years), pregnant women, nursing mothers and patients unable to give consent

Design outcomes

Primary

Measure	Time frame
Determining the guideline and tumor board adherence of gastrointestinal tumor boards - determined by a classification model for adherence assessment, consisting of major and minor criteria, which classifies adherence into 4 categories: complete adherence, partial adherence, no adherence, non-assessable adherence. - Guideline adherence: comparison of the therapy recommendation from the tumor board with the corresponding national guideline recommendation (S3 guidelines of the AWMF and/or Onkopedia guidelines). - Tumor board adherence: comparison of the therapy recommendation from the tumor board with the therapy course (up to 3 months after tumor board date) from the digital, hospital-internal patient file or with treatment information from the Saxon Cancer Registry	—

Measure

Time frame

Determining the guideline and tumor board adherence of gastrointestinal tumor boards - determined by a classification model for adherence assessment, consisting of major and minor criteria, which classifies adherence into 4 categories: complete adherence, partial adherence, no adherence, non-assessable adherence. - Guideline adherence: comparison of the therapy recommendation from the tumor board with the corresponding national guideline recommendation (S3 guidelines of the AWMF and/or Onkopedia guidelines). - Tumor board adherence: comparison of the therapy recommendation from the tumor board with the therapy course (up to 3 months after tumor board date) from the digital, hospital-internal patient file or with treatment information from the Saxon Cancer Registry

—

Secondary

Measure	Time frame
Determining the causes of guideline deviations (for tumor boards with partial or no guideline adherence), and Determining the causes of tumor board deviations in the course of therapy (for tumor boards with partial or no tumor board adherence) - in each case by researching the hospital's internal digital patient file or the tumor board documentation	—

Countries

Germany

Contacts

Public ContactAlina Krause

Universitäres Krebszentrum Leipzig (UCCL)

alina.krause@medizin.uni-leipzig.de0341 - 97 12560

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026